Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2026-05-21 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于上海凯赛生物技术股份有限公司2025年度持续督导工作现场检查报告
Audit Report / Information Classification · 85% confidence The document is a detailed on-site inspection report prepared by the sponsor (中信证券) under Shanghai Stock Exchange continuous supervision guidelines. It contains substantive review of governance, internal controls, disclosure, related-party transactions, use of proceeds, etc., and is not a short announcement or director dealing notice. It is not an annual report, interim report, earnings release, or proxy statement. This is a standalone regulatory inspection/audit‐style report, fitting the ‘Audit Report / Information’ category (AR).
2026-05-21 Chinese
招商证券股份有限公司关于上海凯赛生物技术股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 85% confidence The document is a Chinese securities sponsor’s “2025年度持续督导跟踪报告” filed by 招商证券 as part of its ongoing supervisory obligations under the Shanghai Stock Exchange listing rules. It is not the issuer’s standalone Annual Report (10-K), Interim/Quarterly Report (IR), auditor’s report (AR), earnings release (ER), management discussion (MDA) or any other specialized category. It is a compliance/regulatory disclosure by the sponsor, with no separate “attached” report announcement language, and thus falls under the general Regulatory Filings category (RNS).
2026-05-19 Chinese
关于召开2025年度暨2026年第一季度中英双语业绩说明会的公告
Investor Presentation Classification · 70% confidence The document is an announcement from Shanghai Cathay Biotech of a bilingual performance briefing covering the 2025 annual results and 2026 Q1, including time, format (live webcast and text interaction), platform details, and invited executives. It is not the actual detailed results (Earnings Release) nor the financial statements; rather, it is an invitation notice for an investor presentation event. This aligns with the definition of an Investor Presentation (IP) category.
2026-05-11 Chinese
天健会计师事务所（特殊普通合伙）关于上海凯赛生物技术股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审计报告" regarding non-operating fund occupation and other related party fund transactions for Shanghai Kaisa Biotechnology Co., Ltd. It includes an audit opinion, detailed tables of fund occupation and related party transactions for the fiscal year 2025, and copies of the auditor's professional certificates and licenses. The document is about 6264 characters long, which is sufficient to contain substantive audit content rather than just an announcement. It is not a full annual report (10-K) but a standalone audit report focusing on a specific aspect of the company's financials, namely non-operating fund occupation and related party transactions. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit report with applied accounting principles and audit results, not the full annual report or a regulatory filing announcement. Therefore, the correct classification is AR with high confidence.
2026-04-23 Chinese
2025年度提质增效重回报行动方案的评估报告暨2026年度提质增效重回报行动方案
Management Reports Classification · 95% confidence The document is a detailed report from Shanghai Kaisa Biotechnology Co., Ltd. outlining the evaluation of the 2025 action plan and the 2026 action plan titled 'Quality Improvement, Efficiency Enhancement, and Return to Shareholders.' It covers comprehensive strategic, operational, financial, governance, ESG, investor relations, shareholder return policies including dividends and share repurchases, and executive compensation plans. The content is forward-looking and includes detailed management plans and performance evaluations, which are typical of a Management Discussion and Analysis (MDA) report. It is not a simple announcement or a brief summary but a substantive report with detailed explanations of business trends, financial management, and outlook. There is no indication that this is an annual report (10-K), earnings release (ER), or regulatory filing (RNS). The document length (7559 characters) and depth of content support classification as MDA rather than a short announcement or presentation. Therefore, the most appropriate classification is Management Reports (MDA).
2026-04-23 Chinese
关于公司2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Shanghai Kaisa Bio-Technology Co., Ltd. regarding the 2025 annual status of the company's raised funds, including their deposit, management, and actual usage. It references compliance with the China Securities Regulatory Commission rules and Shanghai Stock Exchange regulations on raised funds. The document includes extensive financial data on fundraising amounts, usage, balances, project investment details, changes in investment projects, and auditor and sponsor opinions on the raised funds usage. It also contains attachments with detailed tables on fund usage and project changes. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to fundraising activities and their management for the fiscal year 2025. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a full annual report or interim report. It is a specialized report focused on fundraising and capital usage, consistent with CAP filings.
2026-04-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.